Home
ELVN
ELVN News

Latest Enliven Therapeutics Inc. (ELVN) News on September 15, 2025

Wall Street Analysts Predict a 106.48% Upside in Enliven Therapeutics, Inc. (ELVN): Here's What You Should Know

Zacks

3 days ago

Wall Street Analysts Predict a 106.48% Upside in Enliven Therapeutics, Inc. (ELVN): Here's What You Should Know

Enliven Therapeutics, Inc. (ELVN) Upgraded to Buy: Here's What You Should Know

Zacks

6 days ago

Enliven Therapeutics, Inc. (ELVN) Upgraded to Buy: Here's What You Should Know

Enliven Therapeutics, Inc. (ELVN) Backed by Goldman Sachs After Strong Trial Data

Insider Monkey

3 months ago

Enliven Therapeutics, Inc. (ELVN) Backed by Goldman Sachs After Strong Trial Data

MT Newswires

3 months ago

Enliven Therapeutics Closes Public Offering

Enliven Therapeutics Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares

PR Newswire

3 months ago

Enliven Therapeutics Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares

MT Newswires

3 months ago

Sector Update: Health Care Stocks Slide Late Afternoon

MT Newswires

3 months ago

Top Midday Gainers

MT Newswires

3 months ago

Enliven Therapeutics Prices $200 Million Public Offering of Common Stock, Pre-Funded Warrants

Enliven Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

PR Newswire

3 months ago

Enliven Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

MT Newswires

3 months ago

Enliven's Chronic Myeloid Leukemia Candidate Achieves MMR Rate in Phase 1 Trial

MT Newswires

3 months ago

Enliven Therapeutics Launches $200 Million Securities Offering

Enliven Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

PR Newswire

3 months ago

Enliven Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Enliven Therapeutics Announces Updated Positive Data from Phase 1 Clinical Trial of ELVN-001 in CML at EHA 2025 Congress

PR Newswire

3 months ago

Enliven Therapeutics Announces Updated Positive Data from Phase 1 Clinical Trial of ELVN-001 in CML at EHA 2025 Congress

7 Luxury Vehicles Expected To Skyrocket in Price Due To Trump’s Tariffs

GOBankingRates

4 months ago

7 Luxury Vehicles Expected To Skyrocket in Price Due To Trump’s Tariffs

3 International Vacations That Are Cheaper Than an iPhone

GOBankingRates

4 months ago

3 International Vacations That Are Cheaper Than an iPhone

Suze Orman’s 5 Best Tips for Saving Money Even When Living Paycheck to Paycheck

GOBankingRates

4 months ago

Suze Orman’s 5 Best Tips for Saving Money Even When Living Paycheck to Paycheck

This week in Trumponomics: Too bad TACO isn’t true

Yahoo Finance

4 months ago

This week in Trumponomics: Too bad TACO isn’t true

Starmer says Farage would spook the City and give us Truss 2 – he could be right

The Guardian

4 months ago

Starmer says Farage would spook the City and give us Truss 2 – he could be right

AI ecosystem isn't just Nvidia: Unlock it further with this ETF

Yahoo Finance Video

4 months ago

AI ecosystem isn't just Nvidia: Unlock it further with this ETF

Is Dave Ramsey's Home Buying Advice Realistic For The Average Homeowner?

Benzinga

4 months ago

Is Dave Ramsey's Home Buying Advice Realistic For The Average Homeowner?

Ford recalls more than 29,000 vehicles in the US, NHTSA says

Reuters

4 months ago

Ford recalls more than 29,000 vehicles in the US, NHTSA says

MT Newswires

4 months ago

Mizuho Adjusts Price Target on Enliven Therapeutics to $41 From $39, Maintains Outperform Rating

Enliven Therapeutics to Present at Upcoming Investor Conferences

PR Newswire

4 months ago

Enliven Therapeutics to Present at Upcoming Investor Conferences

Enliven price target lowered to $27 from $36 at JonesResearch

TipRanks

4 months ago

Enliven price target lowered to $27 from $36 at JonesResearch

Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update

PR Newswire

4 months ago

Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update

Enliven Therapeutics Announces Updated Positive Data from Phase 1 Clinical Trial of ELVN-001 in CML and Oral Presentation at the EHA 2025 Congress

PR Newswire

4 months ago

Enliven Therapeutics Announces Updated Positive Data from Phase 1 Clinical Trial of ELVN-001 in CML and Oral Presentation at the EHA 2025 Congress

Enliven Therapeutics Announces Poster Presentations at the 2025 AACR Annual Meeting

PR Newswire

5 months ago

Enliven Therapeutics Announces Poster Presentations at the 2025 AACR Annual Meeting

Enliven Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

PR Newswire

6 months ago

Enliven Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

Enliven Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference

PR Newswire

7 months ago

Enliven Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference

Enliven Therapeutics (NASDAQ:ELVN) Is In A Good Position To Deliver On Growth Plans

Simply Wall St.

8 months ago

Enliven Therapeutics (NASDAQ:ELVN) Is In A Good Position To Deliver On Growth Plans

Biotech walks a 'tightrope' amid unclear funding, regulations

Yahoo Finance Video

8 months ago

Biotech walks a 'tightrope' amid unclear funding, regulations

MT Newswires

8 months ago

Enliven Therapeutics Insider Sold Shares Worth $685,868, According to a Recent SEC Filing

MT Newswires

9 months ago

BTIG Initiates Enliven Therapeutics at Buy With $42 Price Target

Enliven Therapeutics Reports Third Quarter Financial Results and Provides a Business Update

PR Newswire

10 months ago

Enliven Therapeutics Reports Third Quarter Financial Results and Provides a Business Update

Enliven Therapeutics to Present at the Jefferies London Healthcare Conference

PR Newswire

10 months ago

Enliven Therapeutics to Present at the Jefferies London Healthcare Conference

MT Newswires

a year ago

JonesTrading Initiates Enliven Therapeutics at Buy With $36 Price Target

Why this largely unknown company is one analyst's top biotech pick

Yahoo Finance Video

a year ago

Why this largely unknown company is one analyst's top biotech pick

Enliven Therapeutics’ ELVN-001 shows promise in Phase I CML trial

Clinical Trials Arena

a year ago

Enliven Therapeutics’ ELVN-001 shows promise in Phase I CML trial

Enliven Therapeutics Announces Positive Data Update from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia

GlobeNewswire

a year ago

Enliven Therapeutics Announces Positive Data Update from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia

Here's Why Momentum in Enliven Therapeutics, Inc. (ELVN) Should Keep going

Zacks

a year ago

Here's Why Momentum in Enliven Therapeutics, Inc. (ELVN) Should Keep going

Enliven Therapeutics Announces Details Regarding the Presentation of Updated ELVN-001 Phase 1a Data at the ESH-iCMLf 26th Annual John Goldman Conference on CML

GlobeNewswire

a year ago

Enliven Therapeutics Announces Details Regarding the Presentation of Updated ELVN-001 Phase 1a Data at the ESH-iCMLf 26th Annual John Goldman Conference on CML

Enliven Therapeutics' Leukemia Candidate Could Challenge Pfizer, AstraZeneca In Broader Target Market: Analyst

Benzinga

a year ago

Enliven Therapeutics' Leukemia Candidate Could Challenge Pfizer, AstraZeneca In Broader Target Market: Analyst

Wall Street Analysts See a 58.78% Upside in Enliven Therapeutics, Inc. (ELVN): Can the Stock Really Move This High?

Zacks

a year ago

Wall Street Analysts See a 58.78% Upside in Enliven Therapeutics, Inc. (ELVN): Can the Stock Really Move This High?

MT Newswires

a year ago

Enliven Therapeutics Insider Sold Shares Worth $269,841, According to a Recent SEC Filing

Enliven Therapeutics (NASDAQ:ELVN) Is In A Good Position To Deliver On Growth Plans

Simply Wall St.

a year ago

Enliven Therapeutics (NASDAQ:ELVN) Is In A Good Position To Deliver On Growth Plans

Wall Street Analysts Think Enliven Therapeutics, Inc. (ELVN) Could Surge 43.04%: Read This Before Placing a Bet

Zacks

a year ago

Wall Street Analysts Think Enliven Therapeutics, Inc. (ELVN) Could Surge 43.04%: Read This Before Placing a Bet

Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update

GlobeNewswire

a year ago

Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update

MT Newswires

a year ago

Enliven Therapeutics Insider Sold Shares Worth $1,252,826, According to a Recent SEC Filing

MT Newswires

a year ago

Enliven Therapeutics Insider Sold Shares Worth $259,902, According to a Recent SEC Filing

Enliven Therapeutics to Present at Two Upcoming Investor Conferences

GlobeNewswire

a year ago

Enliven Therapeutics to Present at Two Upcoming Investor Conferences

MT Newswires

a year ago

Enliven Therapeutics Insider Sold Shares Worth $22,877,262, According to a Recent SEC Filing

MT Newswires

a year ago

Enliven Therapeutics Q1 Loss Narrows

Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update

GlobeNewswire

a year ago

Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update

MasterCraft Boat, SentinelOne, and More Stocks See Action From Activist Investors

Barrons.com

a year ago

MasterCraft Boat, SentinelOne, and More Stocks See Action From Activist Investors

Enliven Therapeutics Shares First Look At Safety, Clinical Activity Of Lead Program

Benzinga

a year ago

Enliven Therapeutics Shares First Look At Safety, Clinical Activity Of Lead Program

Enliven Therapeutics Announces Positive Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia

GlobeNewswire

a year ago

Enliven Therapeutics Announces Positive Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia

Enliven Therapeutics Appoints Dr. Lori Kunkel to Board of Directors

GlobeNewswire

a year ago

Enliven Therapeutics Appoints Dr. Lori Kunkel to Board of Directors

Owning 36% shares,institutional owners seem interested in Enliven Therapeutics, Inc. (NASDAQ:ELVN),

Simply Wall St.

a year ago

Owning 36% shares,institutional owners seem interested in Enliven Therapeutics, Inc. (NASDAQ:ELVN),

Enliven Therapeutics to Share Initial Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 and Host Virtual Key Opinion Leader Event on April 11, 2024

GlobeNewswire

a year ago

Enliven Therapeutics to Share Initial Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 and Host Virtual Key Opinion Leader Event on April 11, 2024

Enliven Therapeutics Inc Director Rahul Ballal Sells 13,278 Shares

GuruFocus.com

a year ago

Enliven Therapeutics Inc Director Rahul Ballal Sells 13,278 Shares

Enliven Therapeutics Announces $90 Million Private Placement Financing and Provides Pipeline Updates

GlobeNewswire

a year ago

Enliven Therapeutics Announces $90 Million Private Placement Financing and Provides Pipeline Updates

Enliven Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update

GlobeNewswire

2 years ago

Enliven Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update

Enliven Therapeutics to Present at TD Cowen’s 44th Annual Health Care Conference

GlobeNewswire

2 years ago

Enliven Therapeutics to Present at TD Cowen’s 44th Annual Health Care Conference

Blue Bird Announces Authorization of $60 Million Stock Repurchase Program

Business Wire

2 years ago

Blue Bird Announces Authorization of $60 Million Stock Repurchase Program

When Will Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Turn A Profit?

Simply Wall St.

2 years ago

When Will Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Turn A Profit?

Chuck Royce Adds John B Sanfilippo & Son Inc to Portfolio

GuruFocus.com

2 years ago

Chuck Royce Adds John B Sanfilippo & Son Inc to Portfolio

SRH Total Return Fund, Inc. Section 19(a) Notice

ACCESSWIRE

2 years ago

SRH Total Return Fund, Inc. Section 19(a) Notice

New Strong Sell Stocks for January 30th

Zacks

2 years ago

New Strong Sell Stocks for January 30th

Investors in Dril-Quip (NYSE:DRQ) have unfortunately lost 41% over the last five years

Simply Wall St.

2 years ago

Investors in Dril-Quip (NYSE:DRQ) have unfortunately lost 41% over the last five years

Armada Hoffler’s BBB Credit Rating Confirmed by Morningstar DBRS

GlobeNewswire

2 years ago

Armada Hoffler’s BBB Credit Rating Confirmed by Morningstar DBRS

Grid Dynamics to Announce Fourth Quarter and Full Year 2023 Financial Results on February 22nd

Business Wire

2 years ago

Grid Dynamics to Announce Fourth Quarter and Full Year 2023 Financial Results on February 22nd

Business Wire

2 years ago

Bioceres Crop Solutions to Host Fiscal Second Quarter 2024 Financial Results Conference Call on Thursday, February 8, 2024 at 4:30 p.m. Eastern Time

Q3 Earnings Roundup: Keurig Dr Pepper (NASDAQ:KDP) And The Rest Of The Beverages and Alcohol Segment

StockStory

2 years ago

Q3 Earnings Roundup: Keurig Dr Pepper (NASDAQ:KDP) And The Rest Of The Beverages and Alcohol Segment

3 Stocks to Buy for a Sustainable Agriculture Revolution

InvestorPlace

2 years ago

3 Stocks to Buy for a Sustainable Agriculture Revolution

Inhibrx (INBX) Up 6% on Sale of Rare Disease Drug to Sanofi

Zacks

2 years ago

Inhibrx (INBX) Up 6% on Sale of Rare Disease Drug to Sanofi

Armada Hoffler Receives Surge in Interest for Class-A Office Space at the Interlock

GlobeNewswire

2 years ago

Armada Hoffler Receives Surge in Interest for Class-A Office Space at the Interlock

Newsfile

2 years ago

IAMGOLD Reports Fourth Quarter 2023 Production Results and Commissioning Progress at Côté Gold

15 Small-Cap Stocks with High Potential

Insider Monkey

2 years ago

15 Small-Cap Stocks with High Potential

Bank First (NASDAQ:BFC) Has Announced That It Will Be Increasing Its Dividend To $0.35

Simply Wall St.

2 years ago

Bank First (NASDAQ:BFC) Has Announced That It Will Be Increasing Its Dividend To $0.35

3 Overlooked Small-Cap Stocks Poised to Skyrocket Soon

InvestorPlace

2 years ago

3 Overlooked Small-Cap Stocks Poised to Skyrocket Soon

Regenxbio Inc President and CEO Kenneth Mills Sells 45,000 Shares

GuruFocus.com

2 years ago

Regenxbio Inc President and CEO Kenneth Mills Sells 45,000 Shares

Here's Why We Think Bank First (NASDAQ:BFC) Is Well Worth Watching

Simply Wall St.

2 years ago

Here's Why We Think Bank First (NASDAQ:BFC) Is Well Worth Watching

Range Announces Conference Call to Discuss Fourth Quarter 2023 Financial Results

GlobeNewswire

2 years ago

Range Announces Conference Call to Discuss Fourth Quarter 2023 Financial Results

Angi Inc. to Announce Q4 2023 Earnings on February 13th and Host Earnings Conference Call on February 14th

GlobeNewswire

2 years ago

Angi Inc. to Announce Q4 2023 Earnings on February 13th and Host Earnings Conference Call on February 14th

Bank First Announces Net Income for the Fourth Quarter of 2023

PR Newswire

2 years ago

Bank First Announces Net Income for the Fourth Quarter of 2023

REGENXBIO Announces Positive Interim Data from Phase II AAVIATE® Trial of ABBV-RGX-314 for the Treatment of Wet AMD Using Suprachoroidal Delivery

PR Newswire

2 years ago

REGENXBIO Announces Positive Interim Data from Phase II AAVIATE® Trial of ABBV-RGX-314 for the Treatment of Wet AMD Using Suprachoroidal Delivery

Is Everi Holdings Inc. (NYSE:EVRI) A High Quality Stock To Own?

Simply Wall St.

2 years ago

Is Everi Holdings Inc. (NYSE:EVRI) A High Quality Stock To Own?

Institutional owners may ignore Dyne Therapeutics, Inc.'s (NASDAQ:DYN) recent US$56m market cap decline as longer-term profits stay in the green

Simply Wall St.

2 years ago

Institutional owners may ignore Dyne Therapeutics, Inc.'s (NASDAQ:DYN) recent US$56m market cap decline as longer-term profits stay in the green

Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares

GlobeNewswire

2 years ago

Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares

Associated Press Finance

2 years ago

TechTarget, Chesapeake Energy rise; Hertz Global, KB Home fall, Thursday, 1/11/2024

Reuters

2 years ago

TechTarget to combine with UK-based Informa's digital businesses

TechTarget to Expand Scale and Leadership Position in B2B Data and Market Access through Strategic Combination with Informa Tech’s Digital Businesses

Business Wire

2 years ago

TechTarget to Expand Scale and Leadership Position in B2B Data and Market Access through Strategic Combination with Informa Tech’s Digital Businesses

Federated Hermes Premier Municipal Income Fund declares dividend and announces new Trustee

PR Newswire

2 years ago

Federated Hermes Premier Municipal Income Fund declares dividend and announces new Trustee

Bill Ackman, rarely inclined to back down, escalates his fight against America’s most prestigious universities

CNN Business

2 years ago

Bill Ackman, rarely inclined to back down, escalates his fight against America’s most prestigious universities

embecta Announces FDA 510(k) Submission for Insulin Patch Pump

GlobeNewswire

2 years ago

embecta Announces FDA 510(k) Submission for Insulin Patch Pump

Xarxa Oberta de Catalunya Deploys Infinera’s Optical Transport Solution for Fiber Optic Networks in Catalonia Region

GlobeNewswire

2 years ago

Xarxa Oberta de Catalunya Deploys Infinera’s Optical Transport Solution for Fiber Optic Networks in Catalonia Region

3 Oil Stocks to Offload as the New Year Begins

InvestorPlace

2 years ago

3 Oil Stocks to Offload as the New Year Begins

Quanex Building Products Corp Director Curtis Stevens Sells 4,880 Shares

GuruFocus.com

2 years ago

Quanex Building Products Corp Director Curtis Stevens Sells 4,880 Shares

PAR Technology (PAR) Loyalty Platform to Aid Insomnia Cookies

Zacks

2 years ago

PAR Technology (PAR) Loyalty Platform to Aid Insomnia Cookies

Cassava Sciences Completes Dividend Distribution of Warrants to Shareholders

GlobeNewswire

2 years ago

Cassava Sciences Completes Dividend Distribution of Warrants to Shareholders

Share on Social Networks: